Shaw and Partners is pleased to be appointed as Lead Manager to an equity capital raising by Recce Pharmaceuticals Ltd (ASX.RCE)

The company is undertaking an institutional placement of new securities, to be issued at $1.30 per security to raise up to approximately $27.95 million. New shares issued under the offer will rank pari passu with existing securities.

The offer price of $1.30 per share represents a 20.5% discount to last close of $1.6350, a 20.7% discount to 5-day VWAP of $1.6398 and a 16.1% discount to 20-day VWAP of $1.5492.

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of new classes of synthetic anti-infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.  www.recce.com.au

The offer is available to Australian resident Sophisticated and Professional Investor clients only.

For more information please contact your Shaw and Partners Adviser.